Inaktiver Wert

Andere Sprachen Cyclacel Pharmaceuticals Inc Nasdaq

Aktien

US23254L3069

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

26.06.	Sektor-Update: Aktien des Gesundheitswesens am späten Nachmittag schwächer	MT
26.06.	Sektor-Update: Aktien des Gesundheitswesens geben im Nachmittagshandel nach	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Softer Late Afternoon	26.06.
Sector Update: Health Care Stocks Lower in Afternoon Trading	26.06.
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise	26.06.
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions	26.06.
Cyclacel Pharmaceuticals : A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma	03.06.
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer	03.06.
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000	14.05.
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results	09.05.
Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	02.05.
Top Midday Gainers	30.04.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	30.04.
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	30.04.
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	29.04.
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	02.04.
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	01.04.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	20.03.
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	19.03.
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19.03.
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cyclacel Pharmaceuticals Inc Nasdaq

Aktien

US23254L3069

Andere Sprachen

Filter